Background
Methods
Patients
Patient | Gender | Original disease | Baseline IS | Biopsy date (biopsy #) | Months after LT | Diagnosis |
---|---|---|---|---|---|---|
1 | F | Drug toxicity | CYA, AZA, ST | 18-02-00a | 21 | dnIH |
2 | M | Alcoholic cirrhosis | CYA(N), MMF, ST | 15-03-04a | 58 | dnIH |
3 | M | HCV + alcoholic cirrhosis | CYA(N), ST, anti-CD25 | 13-07-04 (B1)a 05-09-04 (B2) | 32 34 | dnIH |
4 | F | Alcoholic cirrhosis | CYA, MMF, ST | 16-07-04 (B1)a 13-06-05 (B2) | 10 21 | dnIH |
5 | F | Unknown | CYA, MMF, ST | 28-01-10a | 32 | dnIH |
6 | F | PBC | CYA, MMF, ST | 19-04-10a | 13 | dnIH |
7 | F | HCV cirrhosis | CYA, MMF, ST | 30-07-12 (B1) 05-12-12 (B2)a | 3 8 | HCV + AR dnIH |
8 | M | HCV cirrhosis | TAC, ST | 28-12-00a | 14 | dnIH |
9 | F | HCV cirrhosis | CYA, MMF, ST | 18-06-09a | 57 | dnIH |
10 | F | SBC | CYA (N), MMF, ST | 19-02-14a | 87 | dnIH |
11 | F | HCV cirrhosis | CYA, AZA, ST | 25-04-97a | 7 | dnIH |
12 | F | HCV cirrhosis | CYA(N), ST, anti-CD25 | 04-02-02a | 19 | dnIH |
CR-1 | F | HCV cirrhosis | TAC, MMF, ST | 09-11-04 | 29 | CR |
CR-2 | F | PBC | Sotrastaurin | 01-11-11 | 12 | Early CR |
CR-3 | M | Caroli disease | TAC, MMF, ST | 08-03-13 | 17 | CR |
CR-4 | M | Alcoholic cirrhosis + NASH | TAC, MMF, ST, anti-CD25 | 30-07-13 | 6 | Early CR |
CR-5 | M | HCV cirrhosis + HC | CYA, MMF, ST | 07-06-13 | 11 | CR |
CR-6 | M | Cryptogenic | TAC, MMF, ST | 08-03-12 | 9 | Early CR |
CR-7 | M | Re-transplant | TAC, MMF, ST | 05-08-10 | 74 | CR |
CR-8 | M | Alcoholic cirrhosis | TAC, anti-CD25 | 12-03-14 | 84 | CR |
CR-9 | M | PBC | TAC, anti-CD25 | 22-01-07 | 75 | CR |
Cell markers
Immunohistochemistry
Areas of inflammation
Cell quantification
Results
Identification of cellular types found in the inflammatory infiltrates in biopsies from patients with dnIH
Cellular profile of the inflammatory infiltrates in the portal areas in patients with dnIH
Patient | CD138+ IgG4− | CD138+ IgG4+ | CD138+ | CD20+ | CD3+ | CD68+ | Total |
---|---|---|---|---|---|---|---|
Diagnostic biopsies | |||||||
1 | – | – | 600 | 333.3 | 1381.8 | 635.3 | 2950.4 |
2 | – | – | – | 375.7 | 1808.7 | – | |
3 B1 | 808.4 | 52.2 | 860.6 | 668.4 | 1860.9 | 852.3 | 4241.6 |
4 B1 | – | – | 1439.2 | – | – | – | |
5 | 1595 | 40 | 1635 | 1157 | 2019.6 | 2507.3 | 7318.9 |
6 | 1553.5 | 797.9 | 2351.4 | 325.2 | 2116.6 | 1381.5 | 6174.7 |
7 B2 | 935.9 | 160 | 1095.9 | 837.5 | 641.2 | 374 | 2948.6 |
8 | – | – | – | 244,1 | 2051.2 | – | |
9 | 1658.9 | 88.3 | 1747.3 | 613.5 | 2422.7 | 114.9 | 4898.9 |
10 | 899 | 81.3 | 980.3 | 524.5 | 645.2 | 721.2 | 2871.3 |
11 | 599.8 | 89.5 | 689.4 | 735.6 | 1636.6 | 344.3 | 3405.9 |
12 | 286.7 | 533.3 | 820 | 400 | 1008.7 | 466.7 | 2695.3 |
Follow-up biopsies | |||||||
3 B2 | 105.7 | 9.5 | 115.2 | 109.9 | 1296.1 | 630.8 | 215.2 |
4 B2 | 344.5 | 71.8 | 416.3 | 1591.2 | 3226.7 | 530 | 5764.2 |
Recurrent HCV prior to the development of dnIH | |||||||
7 B1 | 227.1 | 154.2 | 381.3 | 295.8 | 838.1 | 779.6 | 2294.8 |
Cellular composition of the inflammatory infiltrates in biopsies from patients with chronic rejection
Patient | CD138+ | CD20+ | CD3+ | CD68+ | Total |
---|---|---|---|---|---|
CR-1 | 587.9 | 1529.4 | 1884.9 | 743.7 | 4745.9 |
CR-2 | 158.7 | 624 | 297.1 | 32.3 | 1112.2 |
CR-3 | 54.9 | 333.3 | 853.3 | 171.4 | 1413 |
CR-4 | 38.9 | 244.6 | 831.4 | 294.6 | 1409.5 |
CR-5 | 5.8 | 864.2 | 2250.7 | 1036.3 | 4157 |
CR-6 | 92.3 | 120 | 966.7 | 33.3 | 1212.3 |
CR-7 | 45.4 | 124.4 | 598.1 | 183.8 | 951.7 |
CR-8 | 11.6 | 1688.9 | 2552.2 | 531 | 4783.7 |
CR-9 | 4.6 | 676.9 | 292.6 | 556.5 | 1530.7 |